Download PDF
Nuklearmedizin 1993; 32(02): 65-72
DOI: 10.1055/s-0038-1629646
Originalarbeiten
Schattauer GmbH

Quantitative Analysis of Anti-CEA Antibody Accumulation in Human Colorectal Carcinomas

R. Bares
1   From the Department of Nuclear Medicine, Technical University, Aachen, FRG
,
J. Fass
2   Department of Surgery, Technical University, Aachen, FRG
,
S. Hauptmann
3   Department of Pathology, Technical University, Aachen, FRG
,
J. Braun
2   Department of Surgery, Technical University, Aachen, FRG
,
O. Grehl
1   From the Department of Nuclear Medicine, Technical University, Aachen, FRG
,
Ruth Reinartz
2   Department of Surgery, Technical University, Aachen, FRG
,
U. Buell
1   From the Department of Nuclear Medicine, Technical University, Aachen, FRG
,
Y. Schumpelick
2   Department of Surgery, Technical University, Aachen, FRG
,
C. Mittermayer
3   Department of Pathology, Technical University, Aachen, FRG
› Author Affiliations
Further Information

Publication History

Received: 09 October 1992

Publication Date:
05 February 2018 (online)

    Permissions and Reprints

Summary

In order to obtain quantitative data on intratumoral antibody accumulation we analyzed resected colorectal adenocarcinomas of 25 patients who had undergone immunoscintigraphy 4-14 days earlier. All had been injected with 0.5-1.0 mg intact anti-CEA antibody (BW 431/26) labelled with 70-80 MBq 131I. Correlation of tissue radioactivity concentrations with tumor characteristics revealed significantly higher values in necrotic compared to viable as well as in CEA-positive compared to CEA-negative viable tumor tissue indicating action of both specific and unspecific uptake mechanisms. In contrast, diagnostic results of immunoscintigraphy were influenced by tumor size only. 11 of 12 falsenegative findings were obtained in tumors <4 cm in diameter. Since ex- vivo scintigraphy of resected specimens correctly visualized all but one of these lesions, it is concluded that technical limitations of scintigraphy are the main cause of negative results of radioimmunoimaging with 131 I-labelled antibodies.

Zusammenfassung

Zur Gewinnung quantitativer Daten über die intratumorale Anreicherung radioaktiv markierter Antikörper wurden Operationspräparate kolorektaler Karzinome von 25 Patienten untersucht, bei denen 4-14 Tage zuvor eine Immunszintigraphie mit 0,5-1,0 mg eines intakten Anti-CEA-Antikörpers (BW 431/26), markiert mit 70-80 MBq 131J, durchgeführt worden war. Ein Vergleich der Radioaktivitätskonzentrationen im Gewebe mit histologischen Befunden ergab signifikant höhere Werte in Nekrosen verglichen mit vitalen Tumoranteilen sowie in CEA-positiven verglichen mit CEA-negativen vitalen Tumorgeweben. Dies spricht für ein gleichzeitiges Vorkommen spezifischer (CEA-abhängiger) und unspezifischer (CEA-unabhängiger) Anreicherungsmechanismen. Die szintigraphischen Resultate hingen entscheidend von der Tumorgröße ab: 11 von 12 falsch-negativen Befunden wurden bei Tumoren eines Durchmessers <4 cm erhoben. Da diese mit Ausnahme eines Herdes durch Ex-vivo-Szintigrannme des Operationspräparats korrekt lokalisiert werden konnten, dürften meßtechnische Limitationen die Hauptursache negativer Befunde der ln-vivo-lmmunszintigraphie mit 131J-markierten Antikörpern sein.

Key words

Carcinoembryonic antigen - colorectal carcinoma - immunoscintigraphy - tumor necroses

Schlüsselwörter

Karzinoembryonales Antigen - kolorektale Karzinome - Immunszintigraphie - Tumornekrosen
 

  • REFERENCES

  • 1 Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139: 846-51.
    CrossrefPubMedGoogle Scholar
  • 2 Bares R, Fass J, Hauptmann S. et al. Technical limitations of immunoscintigraphy with 99mTechnetium labelled intact anti-CEA antibodies: Comparison of in-vivo and ex- vivo scintigrams and correlation with tumor size, localization, CEA-expression, and tissue radioactivity concentrations. J Nucl Med 1992; 33: 1001.
    Google Scholar
  • 3 Beatty JD, Duda RB, Williams LE. et al. Preoperative imaging of colorectal carcinoma with 11 ‘in-labelled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986; 46: 6494-502.
    PubMedGoogle Scholar
  • 4 Bosslet K, Lueben G, Schwarz A. et al. Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes on carcinoem- bryonic antigen. Int J Cancer 1985; 36: 75-84.
    CrossrefPubMedGoogle Scholar
  • 5 Bosslet K, Steinstraesser A, Schwarz A. et al. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 1988; 14: 523-8.
    PubMedGoogle Scholar
  • 6 Chatal JF, Peltier P, Bardies M. et al. Docs immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?. Eur J Nucl Med 1992; 19: 205-13.
    PubMedGoogle Scholar
  • 7 Colcher D, Esteban JM, Carrasquillo JA. et al. Quantitative analysis of selective radiolabelled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987; 47: 1185-9.
    PubMedGoogle Scholar
  • 8 Duran-Reynals F. Studies on the localization of dyes and foreign proteins in normal and malignant tissues. Am J Cancer 1939; 35: 98-107.
    Google Scholar
  • 9 Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that arc leaky to circulating macromolccules. Am J Pathol 1988; 133: 95-109.
    PubMedGoogle Scholar
  • 10 Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. Limitations of radiolabelled monoclonal antibodies for localization of human neoplasms. Cancer Res 1986; 46: 3183-91.
    PubMedGoogle Scholar
  • 11 Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48: 5842-8.
    PubMedGoogle Scholar
  • 12 Esteban JM, Schlom J, Mornex F, Colcher D. Radioimmunothcrapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effccts on tumors and normal organs. Eur J Clin Oncol 1987; 23: 643-5.
    CrossrefPubMedGoogle Scholar
  • 13 Fand I, Sharkey RM, Primus FJ, Cohen SA, Goldcnberg DM. Relationship of radioantibody localization and cell viability in a xenografted human cancer model as measured by wholc-body autoradiography. Cancer Res 1987; 47: 2177-83.
    PubMedGoogle Scholar
  • 14 Hagan PL, Halpern SE, Dillman RO. et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986; 27: 422-7.
    PubMedGoogle Scholar
  • 15 Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategics. J Ntl Cancer Inst 1989; 81: 570-6.
    Google Scholar
  • 16 Juwcid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglobulin G at focal sites of inflammation. Eur J Nucl Med 1992; 19: 159-65.
    PubMedGoogle Scholar
  • 17 Keenan AM. Radiolabelled monoclonal antibodies: current status and future outlook. In: Nuclear Medicine Annual, Freeman LM, Weissmann HS. eds. New York: Raven Press; 1988
    Google Scholar
  • 18 Moshakis V, McIIhinncy RAJ, Raghavan D, Neville AM. Localization of human tumour xenografts after iv administration of radiolabelled monoclonal antibodies. Br J Cancer 1981; 44: 91-9.
    CrossrefPubMedGoogle Scholar
  • 19 Primus FJ, Wang RH, Sharkey RM, Goldenberg DM. Detection of carcinoembryo- nic antigen in tissue sections by immunopcr- oxidasc. J Immunol Meth 1975; 08: 267-76.
    CrossrefPubMedGoogle Scholar
  • 20 Sands H. Experimental studies of radioimmunodetection of cancer: an overview. Cancer Res 1990; 50: 809-13.
    Google Scholar
  • 21 Williams LE, Duda RB, Profitt RT. et al. Tumor uptake as a function of tumor mass: a mathematical model. J Nucl Med 1988; 29: 103-9.
    PubMedGoogle Scholar